children have a higher incidence of seizures. Recent studies have shown that neurological and cognitive deficits may persist in long-term survivors of CM. In African children, deficits in attention , memory and visual skills, speech and language have been reported (5) . Some of these effects have also been observed in other forms of malaria less severe than cerebral malaria such as malaria with multiple convulsions but no prolonged loss of consciousness (3) . It is also known that malaria may affect hearing, with hearing loss being reported as a complication of severe malaria (6, 7) . However, since antimalarial drugs are sometimes indicated for use in non-malarious conditions such as prophylaxis in healthy subjects, the comparison of drug effects in nonmalarious conditions with those observed in the context of malaria can give useful information on toxicity attributable to antimalarial drugs.
Antimalarial drugs have selective actions on the different phases of the parasite life cycle, and may be indicated either for chemotherapy or chemoprophylaxis. They can be divided as follows 
Sulphonamides, Doxycycline
To reduce the pace of selection of drug resistance, the World Health Organisation (WHO) now recommends that all antimalarial therapies be deployed as combinations that include an artemisinin derivative as one of the partner drugs, a strategy referred to as artemisinin combination therapy (ACT) (8, 9) .
Neurotoxicity has been reported for many of the antimalarial drugs. Choroquine prophylaxis has been associated with retinal dysfunction, and in high doses causes seizures and coma (10) . Quinine affects the auditory system causing reversible sensorineural hearing loss, tinnitus and vertigo (11) .
The prophylactic use of mefloquine causes irreversible ototoxicity in healthy subjects (12) .
Mefloquine has also been associated with severe dose dependent neuropsychiatric adverse reactions such as anxiety, delusions, hallucinations and psychosis (13) . Lumefantrine, like mefloquine, is a phenanthrene methanol derivative of quinine and has a moderately long terminal elimination half-life in malaria patients of 3-6 days (14, 15) . Although lumefantrine has not been reported to be neurotoxic in the clinical setting, it has been suggested that the prolonged exposure of auditory neurons to lumefantrine, as occurs under therapy with artemetherlumefantrine combination may sensitize neurons to harm by artemisinins, with cumulative harm occurring with successive dosing (16) .
Whilst it has been reported that artemisinin antimalarials are well tolerated with few side effects (17) (18) (19) (20) (21) , their association with neurotoxicity in animal models has raised concerns about their safety in humans (22) . The neuropathology observed in animals is unusual, appearing to selectively damage parts of the brainstem nuclei, particularly those involved in hearing and balance (23) . In humans, hearing loss, ataxia and tremor have been reported (24) . The prolonged presence of artemisinins upon slow release from oil-based intramuscular formulations appears to be the main cause of observed toxicity in preclinical animal studies (25, 26) . Although several studies have failed to demonstrate toxicity attributable to oral artemisinins in humans (27, 28) , a recent study concerning
Mozambican construction workers raised concerns and renewed interest in auditory impairment with artemether-lumefantrine (AL) when taken for uncomplicated malaria (24, 29) . In this study, no correlation was found between the degree of hearing loss and the time interval separating AL exposure and the follow-up audiogram, suggesting AL associated hearing loss to be irreversible (16, 24) . In support of this, in vitro studies suggest that artemisinin neurotoxicity does not manifest immediately upon exposure, but that once commenced it is inevitable and irreversible; extrapolation from in vitro data suggests that 14 days may possibly be required for full development (24, 30) . In practice artemisinins are often used in combination with other potentially neurotoxic antimalarials, making it difficult to attribute neurotoxicity to the artemisinin component alone.
Neurological impairment is associated with morbid consequences, and continues to place a big socio-economic burden, especially in developing countries which have few resources to deal with such problems. Children are particularly more vulnerable, as effects of neurotoxicity, particularly hearing or visual impairment may affect the child's linguistic, cognitive and educational developments later on in life (31) . The benefits of artemisinin combination therapy have been demonstrated in a large meta-analysis of nearly 6000 patients which shows that combining existing antimalarial drugs with an artemisinin derivative reduces patients risk of treatment failure (by 75%) and lessens the pool of infectious parasites (gametocytes) that transmit the disease to others, an effect that is of both clinical and public health benefit (32) .
However, whilst these studies have clearly demonstrated that ACT is efficacious and have promoted the wide deployment of these combination therapies in Africa and Asia, uncertainty remains over the potential neurotoxicity of artemisinins, and whether combining artemisinins with other potentially neurotoxic antimalarials may increase the risk of harm. This systematic review of the available literature on neurotoxicity of antimalarial drugs aims to inform policy and guide best practice regarding the use of antimalarial drug combinations in chemoprophylaxis and treatment. We propose to identify antimalarials with the least neurotoxic effects, when used alone or in combination, information which together with efficacy data, would be useful when choosing the most suitable antimalarials for ACT.
Review Question/Objective
The objective of this systematic review is to examine the neurotoxic effects of antimalarial drugs.
More specifically, we propose to identify which antimalarials have the least neurotoxic effects, information which together with efficacy data would be useful in choosing the most suitable antimalarials for combination therapy.
Inclusion criteria

Types of studies
The review will consider randomized controlled trials. In the absence of any RCTs, other quantitative study designs such as quasi randomized controlled trails, non-randomized controlled trials, case control studies, clinical studies, before and after studies and cohort studies will be considered for inclusion in a narrative summary. This will enable the identification of current best evidence regarding the use of antimalarial drugs in combination therapy.
Types of Participants
The types of participants in the studies being reviewed will include adults and children with no specific age limitation.
Types of Interventions
We will review studies that evaluate combinations of antimalarial drugs.
Types of outcome
We will evaluate studies that consider the following outcome measures: neurotoxicity, which is defined as effects on the central and /or peripheral nervous system.
Search Strategy
The search strategy aims to find both published and unpublished studies published in English language between 1966-2007. A three-step search strategy will be used in each component of this review. An initial search of MEDLINE, CINAHL, Cochrane Library and EMBASE will be undertaken followed by analysis of the text words contained in the title and abstract, and of the index terms used to describe article. A second search using all identified keywords and index terms will then be undertaken across all included databases. Thirdly, the reference list of all identified reports and articles will be searched for additional studies. between the reviewers will be resolved through discussion, or with a third reviewer.
Data collection/extraction
Data extraction will be managed using the appropriate JBI data extraction tool [Appendix 2]. In some cases revision of the data extraction tool will occur after the full search has been conducted.
Data synthesis
Quantitative papers will, where possible be pooled in statistical meta-analysis using the Joanna Briggs Institute Meta Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI)
[Appendix 3: Synthesis tool]. All results will be subject to double data entry. Odds ratio (for categorical data) and weighted mean differences (for continuous data) and their 95% confidence intervals will be calculated for analysis. Heterogeneity will be assessed using the standard Chisquare. Where statistical pooling is not possible the findings will be presented in a narrative form.
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